Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib
Mariko Minami
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorTakeshi Arita
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorHiromi Iwasaki
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Department of Haematology, National Kyushu Medical Centre, Fukuoka, Japan
Search for more papers by this authorTsuyoshi Muta
Department of Haematology/Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan
Search for more papers by this authorTakatoshi Aoki
Department of Haematology, Harasanshin Hospital, Fukuoka, Japan
Search for more papers by this authorKenichi Aoki
Department of Haematology/Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan
Search for more papers by this authorSatoshi Yamasaki
Department of Haematology, National Kyushu Medical Centre, Fukuoka, Japan
Search for more papers by this authorTakamitsu Matsushima
Department of Medicine and Bioregulatory Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorKoji Kato
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorKatsuto Takenaka
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorKazuki Tanimoto
Department of Haematology and Oncology, Japanese Red Cross Society, Fukuoka Red Cross Hospital, Fukuoka, Japan
Search for more papers by this authorTomohiko Kamimura
Department of Haematology, Harasanshin Hospital, Fukuoka, Japan
Search for more papers by this authorRyosuke Ogawa
Department of Haematology/Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan
Search for more papers by this authorKoichi Akashi
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorCorresponding Author
Toshihiro Miyamoto
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Correspondence: Toshihiro Miyamoto, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
E-mail: [email protected]
Search for more papers by this authorMariko Minami
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorTakeshi Arita
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorHiromi Iwasaki
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Department of Haematology, National Kyushu Medical Centre, Fukuoka, Japan
Search for more papers by this authorTsuyoshi Muta
Department of Haematology/Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan
Search for more papers by this authorTakatoshi Aoki
Department of Haematology, Harasanshin Hospital, Fukuoka, Japan
Search for more papers by this authorKenichi Aoki
Department of Haematology/Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan
Search for more papers by this authorSatoshi Yamasaki
Department of Haematology, National Kyushu Medical Centre, Fukuoka, Japan
Search for more papers by this authorTakamitsu Matsushima
Department of Medicine and Bioregulatory Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorKoji Kato
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorKatsuto Takenaka
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorKazuki Tanimoto
Department of Haematology and Oncology, Japanese Red Cross Society, Fukuoka Red Cross Hospital, Fukuoka, Japan
Search for more papers by this authorTomohiko Kamimura
Department of Haematology, Harasanshin Hospital, Fukuoka, Japan
Search for more papers by this authorRyosuke Ogawa
Department of Haematology/Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan
Search for more papers by this authorKoichi Akashi
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Search for more papers by this authorCorresponding Author
Toshihiro Miyamoto
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Correspondence: Toshihiro Miyamoto, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
E-mail: [email protected]
Search for more papers by this authorSummary
Pulmonary hypertension (PH) is a rare, but life-threatening, adverse event in patients treated with tyrosine kinase inhibitors (TKIs), such as dasatinib, but has not been fully evaluated in patients treated with imatinib or nilotinib. We used echocardiography to noninvasively assess the incidence of PH in 105 patients with chronic myeloid leukaemia (CML) treated with imatinib (n = 37), nilotinib (n = 30) or dasatinib (n = 38). The mean triscupid regurgitation peak gradient (TRPG), which reflects pulmonary arterial pressure, was 22·7 mmHg in the imatinib group, 23·1 mmHg in the nilotinib group and 23·4 mmHg for dasatinib group. These values were not significantly different, but higher than those (19·0 mmHg) in newly diagnosed CML patients. A TRPG > 31 mmHg, marking possible PH onset, was detected in 9 of 105 patients: one (2·7%) treated with imatinib, three (10·0%) with nilotinib and five (13·2%) with dasatinib. Only three patients complained of dyspnoea, whereas the other six were asymptomatic. In addition, there was a tendency toward correlation of TRPG value and age or TKI treatment duration. These results suggested that treatment with not only dasatinib, but also imatinib and nilotinib, can be associated with subclinical PH. Noninvasive echocardiography is useful for screening, especially in older patients with long-term TKI treatment.
Supporting Information
| Filename | Description |
|---|---|
| bjh14608-sup-0001-FigS1.tiffTIFF image, 33.8 MB | Fig S1. Comparisons of WBC and platelet counts with TRPG values of the patients of the control group. |
| bjh14608-sup-0002-Legend.docxWord document, 37.4 KB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- Adir, Y. & Humbert, M. (2010) Pulmonary hypertension in patients with chronic myeloproliferative disorders. European Respiratory Journal, 35, 1396–1406.
- Barst, R.J. (2005) PDGF signaling in pulmonary arterial hypertension. The Journal of Clinical Investigation, 115, 2691–2694.
- Deininger, M.W., Kopecky, K.J., Radich, J.P., Kamel-Reid, S., Stock, W., Paietta, E., Emanuel, P.D., Tallman, M., Wadleigh, M., Larson, R.A., Lipton, J.H., Slovak, M.L., Appelbaum, F.R. & Druker, B.J. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. British Journal of Haematology, 164, 223–232.
- Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031–1037.
- Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. & Larson, R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 2408–2417.
- Dumitrescu, D., Seck, C., ten Freyhaus, H., Gerhardt, F., Erdmann, E. & Rosenkranz, S. (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. European Respiratory Journal, 38, 218–220.
- Fossard, G., Blond, E., Balsat, M., Morisset, S., Giraudier, S., Escoffre-Barbe, M., Labussiere-Wallet, H., Heiblig, M., Bert, A., Etienne, M., Drai, J., Sobh, M., Redonnet-Vernhet, I., Lega, J.C., Mahon, F.X., Etienne, G. & Nicolini, F.E. (2016) Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients. Haematologica, 101, e86–e90.
- Frost, A.E., Barst, R.J., Hoeper, M.M., Chang, H.J., Frantz, R.P., Fukumoto, Y., Galie, N., Hassoun, P.M., Klose, H., Matsubara, H., Morrell, N.W., Peacock, A.J., Pfeifer, M., Simonneau, G., Tapson, V.F., Torres, F., Dario Vizza, C., Lawrence, D., Yang, W., Felser, J.M., Quinn, D.A. & Ghofrani, H.A. (2015) Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 34, 1366–1375.
- Galie, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barbera, J.A., Beghetti, M., Corris, P., Gaine, S., Gibbs, J.S., Gomez-Sanchez, M.A., Jondeau, G., Klepetko, W., Opitz, C., Peacock, A., Rubin, L., Zellweger, M., Simonneau, G., Vahanian, A., Auricchio, A., Bax, J., Ceconi, C., Dean, V., Filippatos, G., Funck-Brentano, C., Hobbs, R., Kearney, P., McDonagh, T., McGregor, K., Popescu, B.A., Reiner, Z., Sechtem, U., Sirnes, P.A., Tendera, M., Vardas, P., Widimsky, P., Sechtem, U., Al Attar, N., Andreotti, F., Aschermann, M., Asteggiano, R., Benza, R., Berger, R., Bonnet, D., Delcroix, M., Howard, L., Kitsiou, A.N., Lang, I., Maggioni, A., Nielsen-Kudsk, J.E., Park, M., Perrone-Filardi, P., Price, S., Domenech, M.T.S., Vonk-Noordegraaf, A. & Zamorano, J.L. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 30, 2493–2537.
- Ghofrani, H.A., Seeger, W. & Grimminger, F. (2005) Imatinib for the treatment of pulmonary arterial hypertension. New England Journal of Medicine, 353, 1412–1413.
- Ghofrani, H.A., Morrell, N.W., Hoeper, M.M., Olschewski, H., Peacock, A.J., Barst, R.J., Shapiro, S., Golpon, H., Toshner, M., Grimminger, F. & Pascoe, S. (2010) Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. American Journal of Respiratory and Critical Care Medicine, 182, 1171–1177.
- Guignabert, C., Phan, C., Seferian, A., Huertas, A., Tu, L., Thuillet, R., Sattler, C., Le Hiress, M., Tamura, Y., Jutant, E.M., Chaumais, M.C., Bouchet, S., Maneglier, B., Molimard, M., Rousselot, P., Sitbon, O., Simonneau, G., Montani, D. & Humbert, M. (2016) Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. The Journal of Clinical Investigation, 126, 3207–3218.
- Hennigs, J.K., Keller, G., Baumann, H.J., Honecker, F., Kluge, S., Bokemeyer, C., Brummendorf, T.H. & Klose, H. (2011) Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulmonary Medicine, 11, 30.
- Hoeper, M.M., Barst, R.J., Bourge, R.C., Feldman, J., Frost, A.E., Galie, N., Gomez-Sanchez, M.A., Grimminger, F., Grunig, E., Hassoun, P.M., Morrell, N.W., Peacock, A.J., Satoh, T., Simonneau, G., Tapson, V.F., Torres, F., Lawrence, D., Quinn, D.A. & Ghofrani, H.A. (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation, 127, 1128–1138.
- Hong, J.H., Lee, S.E., Choi, S.Y., Kim, S.H., Jang, E.J., Bang, J.H., Park, J.E., Jeon, H.R., Oh, Y.J., Yi, J.E., Jung, H.O., Youn, H.J. & Kim, D.W. (2015) Reversible pulmonary arterial hypertension associated with dasatinib for chronic myeloid leukemia. Cancer Research Treatment, 47, 937–942.
- Jabbour, E., Deininger, M. & Hochhaus, A. (2010) Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia, 25, 201–210.
- Jabbour, E., Kantarjian, H.M., Saglio, G., Steegmann, J.L., Shah, N.P., Boque, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., Baccarani, M., Kim, D.W., Bradley-Garelik, M.B., Mohamed, H., Wildgust, M. & Hochhaus, A. (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood, 123, 494–500.
- Jain, P., Kantarjian, H., Sasaki, K., Jabbour, E., Dasarathula, J., Nogueras Gonzalez, G., Verstovsek, S., Borthakur, G., Wierda, W., Kadia, T., Dellasala, S., Pierce, S., Ravandi, F., O'Brien, S. & Cortes, J. (2016) Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. British Journal of Haematology, 173, 114–126.
- Kanda, Y. (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplantation, 48, 452–458.
- Larson, R.A., Hochhaus, A., Hughes, T.P., Clark, R.E., Etienne, G., Kim, D.W., Flinn, I.W., Kurokawa, M., Moiraghi, B., Yu, R., Blakesley, R.E., Gallagher, N.J., Saglio, G. & Kantarjian, H.M. (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 26, 2197–2203.
- Lee, S.-E., Kim, S.-H., Choi, S.-Y., Park, J.-E., Jeon, H.-R., Jang, E.-J. & Kim, D.-W. (2013) Six-year follow-up of dasatinib-related pulmonary arterial hypertension (PAH) for chronic myeloid leukemia in single center. Blood (ASH Annual Meeting Abstracts), 122, 4017.
- Mattei, D., Feola, M., Orzan, F., Mordini, N., Rapezzi, D. & Gallamini, A. (2009) Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplantation, 43, 967–968.
- Montani, D., Bergot, E., Gunther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., Poubeau, P., Girerd, B., Natali, D., Guignabert, C., Perros, F., O'Callaghan, D.S., Jais, X., Tubert-Bitter, P., Zalcman, G., Sitbon, O., Simonneau, G. & Humbert, M. (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 125, 2128–2137.
- Morishita, S., Hagihara, M., Itabashi, M., Ishii, Y., Yamamoto, W., Numata, A., Motohashi, K., Matsumoto, K., Fujisawa, S. & Nakajima, H. (2016) Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia. Rinsho Ketsueki, 57, 999–1003.
- Moslehi, J.J. & Deininger, M. (2015) Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. Journal of Clinical Oncology, 33, 4210–4218.
- Nagasaki, J., Aoyama, Y., Nomoto, Y., Ido, K., Ichihara, H. & Mugitani, A. (2016) Reversible dasatinib-related pulmonary arterial hypertension in a CML patient. Rinsho Ketsueki, 57, 618–623.
- Ong, J., Yeung, D., Filshie, R., Hughes, T.P. & Nandurkar, H. (2015) Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. International Journal of Hematology, 102, 639–642.
- Orlandi, E.M., Rocca, B., Pazzano, A.S. & Ghio, S. (2012) Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leukemia Research, 36, e4–e6.
- Pullamsetti, S.S., Berghausen, E.M., Dabral, S., Tretyn, A., Butrous, E., Savai, R., Butrous, G., Dahal, B.K., Brandes, R.P., Ghofrani, H.A., Weissmann, N., Grimminger, F., Seeger, W., Rosenkranz, S. & Schermuly, R.T. (2012) Role of Src tyrosine kinases in experimental pulmonary hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 32, 1354–1365.
- Quintas-Cardama, A., Kantarjian, H., O'Brien, S., Borthakur, G., Bruzzi, J., Munden, R. & Cortes, J. (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. Journal of Clinical Oncology, 25, 3908–3914.
- Rasheed, W., Flaim, B. & Seymour, J.F. (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leukemia Research, 33, 861–864.
- Rocha, A., Azevedo, I. & Soares, R. (2007) Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells. Angiogenesis, 10, 279–286.
- Sano, M., Saotome, M., Urushida, T., Katoh, H., Satoh, H., Ohnishi, K. & Hayashi, H. (2012) Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert. Internal Medicine, 51, 2337–2340.
- Schermuly, R.T., Dony, E., Ghofrani, H.A., Pullamsetti, S., Savai, R., Roth, M., Sydykov, A., Lai, Y.J., Weissmann, N., Seeger, W. & Grimminger, F. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. The Journal of Clinical Investigation, 115, 2811–2821.
- Seferian, A. & Simonneau, G. (2013) Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? European Respiratory Reviews, 22, 217–226.
- Shah, N.P., Wallis, N., Farber, H.W., Mauro, M.J., Wolf, R.A., Mattei, D., Guha, M., Rea, D. & Peacock, A. (2015) Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. American Journal of Hematology, 90, 1060–1064.
- Wang, H.C., Lee, C.S. & Liu, T.C. (2015) Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography. Kaohsiung Journal of Medical Sciences, 31, 165–166.
- Yap, L.B., Ashrafian, H., Mukerjee, D., Coghlan, J.G. & Timms, P.M. (2004) The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clinical Biochemistry, 37, 847–856.
- Yock, P.G. & Popp, R.L. (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation, 70, 657–662.
- Yun, S., Anwer, F. & Vincelette, N.D. (2014) Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia. BMJ Case Reports, 2014, doi:10.1136/bcr-2014-204477.
10.1136/bcr‐2014‐204477 Google Scholar
- Zakrzewski, D., Seferynska, I., Warzocha, K. & Hryniewiecki, T. (2012) Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia. International Journal of Hematology, 96, 132–135.
Citing Literature
